pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-125b-2 |
Genomic Coordinates | chr21: 16590237 - 16590325 |
Synonyms | MIRN125B2, MIR125B2 |
Description | Homo sapiens miR-125b-2 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-125b-2-3p | ||||||||||||||
Sequence | 54| UCACAAGUCAGGCUCUUGGGAC |75 | ||||||||||||||
Evidence | Experimental | ||||||||||||||
Experiments | Cloned | ||||||||||||||
Editing Events in miRNAs |
|
||||||||||||||
SNPs in miRNA |
|
||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SYT2 | ||||||||||||||||||||
Synonyms | CMS7, MYSPC, SytII | ||||||||||||||||||||
Description | synaptotagmin 2 | ||||||||||||||||||||
Transcript | NM_001136504 | ||||||||||||||||||||
Other Transcripts | NM_177402 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SYT2 | |||||||||||||||||||||
3'UTR of SYT2 (miRNA target sites are highlighted) |
>SYT2|NM_001136504|3'UTR 1 ACAGCAGCGGCTGGGACCCCACACCTTTCACGGACACTGACAAGATCCAGAGCTATCAATACCTCAGTTATGCAACCTTA 81 GAGGTTTTCTTTTTTCTTTCATTTGTTGGGTGGTTGTGTCCTTGTTTTTCCTTGTTTTTCTCTTTTTAAAGACCAACTTC 161 CCTTTGATGGCTGTGTGAGGAGAGTCCCCTAAGAGGTGAAAGAGAAGCCTGGCTCTGTTCACGGTCCCAGGAGCTGTCCT 241 TGCTGCATGCCCTGTCACAGTTCCCTCGACTCTTTCAAAGCTTCACATCTGCCTCACCCCAAGCGAGGCTCTCTACTGGC 321 ACAAACTTGCAGCAGTTCCTGTTTTTTGAGCCTTCTGGACCAACAAAATGGCAGCACATCCTGCTTCCTGACAGGGAAGG 401 CATCACAGTGGCCAATGATCGTGTGTGTGTGTGTGTGTGTGTGTGTGTATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 481 GTGTGTGTCTTTGAGCATTTCTCTTCATTCCTGGAATGTGTGTGTGTGTGTGTCTCTTTGAGCATCTCTCTTCATTCCTG 561 GAATGAGCCATGGACAGTAAAGTTGTGTGGGAAAAGAAGGCTCTTTGGGGACCCTGACATGAAGAAGTCCACTAAGTGGG 641 AGATCTTCTCTCATCTATGGCAAAGTCTCAGGATCCTGTTCAGATATCGGGGCTTTCATACTCCTGTTGGTGGCTATTTG 721 GGAGGCAGCAAGATGTGAAGACTGGATGTGTTCAGAACTAGGACCAAACGATGCCATCAAATACTTCCTCCTGCCAGTCA 801 TGGTTTCCCCAGAAGTGTAGTTCCTGGGACATTCATGGATATGAGCTATTCACTAGTTGGGTCAGACTAACAGGGACTCT 881 CAGTCCCAAAATCTCACTCTTATTGACAATAAATATCAAACTATGAAGAAACAGAAGTCCCATTACCAGAAAGACCAAAA 961 TTAAACTCCTGGATCTTCACCCCATCCAGTGGGAAACACAGATGCTTTCTCCCTTTCCAGAATATAAGCAGCCAAGTTCA 1041 TTTGCATTTATTCCCCATTGTGCTTTTGCTTCTGTTTCTCTTTTAAGTGGAGCAACACTGTCTGAAGACACGTTATCTGT 1121 GCAGAGCCAGAGAACTTTAAAAGGAAAGTTTAAATGTTCTTAGTTCTCCTGAGGTCCAGGTAAGAAGGGGGTGGTAAGAA 1201 GAGGATGGGGGACAGATGGCTGAGATCCCTTGGGAGGAGATATAGGGGAGCACTGGAATTCCCCCGACTCCCACTCCTTG 1281 CTCCCTTGGCCCTCTGCCCTCCATGCTGGAGAGCTGATAGGTAGCTGGAGTGGCCCAGGGAGACCTATGGGAAGGACCCG 1361 TCCTACCATTAGGGGGCTTCTCTCTATGAATGCTAAGAAACAAAGGGCATCCATTCCAAATGAGTAGCAGAGGTGACCTT 1441 CTAGGGTTTCTACCCATGCTCAGTTGTATCCCATTCCCTGTTCACCTTTTGTCCCCAGCACTGATATAAAAGCCATATAT 1521 ATGTTAGTCAGGTTTGCACTGAGTCTTCTTCCAATCCTTCAGCCTGGACAACAGAGTGAGGTCCCCTTGTGGCCAGAGGC 1601 CAGCCCTCCTTGCCTGCCTTCCTTTGACCTCTCTTTTCCATCCATGAAGCCCTCAGGCCCTTGCCATTTTTTCACCACAG 1681 AAAACTCATGGCTTCTCCAGAAGCCTGAGTATCTCTCTTTCCCAGCACAAATGGCAGCATCTCTATCCTGCCCCATCTGG 1761 GCCACTTCAGCTTCCTGTAGACACCCAAGACAGATGGACAGTGTTGGAGGGAATCAGGCTTTGAGGATCCAGTGTGAAGA 1841 AGTTGCAGAGTGTCTTTTTATTTTATTTTAAAAAGGGGGAAGGGGCTTTTGGTTTTGCTTTGTTTTTTGGATGAAGGAGT 1921 GAGGGAAATGAGGGAATACCCCCACCAGAAACAGACTGGAAAGCCTGCCTGTCTCTTGGAGATCCTTCTTTGTCTTGTTA 2001 GTGGTACATGGGAAGTTATGTTTTTACTGGTGTGTGTGTGTGTGTGTGTGTGTGTACTTAATGATGGGAAGGTAAGACTC 2081 TGATCAGGATTATGAACTGCGGTCCTTGGGACCAAAGGTGTGGTCATGGTAGAGAGTTGTAGGACAATAGGGTGTTTTCA 2161 GAATCTGGGTGGCCACAGAGTGGGATTTCCTGGTATGGACATCAGAAGTCACTGGACTCTTCTCCCAACCCCAGAGTTAT 2241 GGGATTTTGGTGCTTTCTCAGGGTCTCTCCCCAGACTCACTCTTCTCACCCATATCCCACAGACTCACTCATGGAGACCC 2321 CCTTGTCAATATCCCCTCTACCTTTACTCCTTTGCCCTTTCCCAATTCATCTTCTACCACCTGGATTCTTTTCCATTCAT 2401 GAACTTCATTCAGCCCTTCCAAAGCCCAAGATTTGCATTCCCTTGACAGGGAGGAAAGGCAATGGTAGGAACCTCTGGTG 2481 GTCTGGGTGTCTATGTGCCTGGTGACCAGGGCTGGATTTTTATTACTCTGAGCCCACTGCTAGTGAGGAGCCTTGAGGGG 2561 TGGGGACAGGTTGCTGAGTGATTTTGAACGTTGACACCAGTGTGGAGCCAGTGTGGGTGTGGGGAGCAGTGCCTTCCTCA 2641 GGTCCCAGCTGGTCCTGATATGCCACGTAGTGGATGGCATCTGTCTTGGTCCATGGGCTTGGTGGGAACATGCTTCTGCT 2721 TGTGTGTTTTCCATACCTGAGGGCTGACGTAGCTTAAACCACAGGGCATCATGCCAAACACTCACTGCTGGGCAGGTTTA 2801 TTTCTGGGGATGTCAGGGTACTGGGGTGTAGGCACTAAGCAGGATAGAGTTAGGGTGTCTGGCTAGTAAGGGGTTCTGGA 2881 CGCCTCTGGGGCTGTGAGTTTTCATCTCAAAGTCTGTTCCAGAGAAAGGAAAGTAGTATAGAGGTGATTTTTAGAGAAGC 2961 TGAGACCATGAAAACAAGCCTAATCCCATCCAGAAACTGGGGTAAAGTCTGAAAGTTCGTTTTCTTCTTCCTCCCTGAAT 3041 AATTGTTCCAGAAGGGATGCTAACTCTGCCAGAGCTACAGGCAGATTTTTGGGCTTTGGAAGTGGAAGCTGAGGCCTGGG 3121 GAAGGCTGGGTAAGGAATGCTGGGGCAATCTCAGACAGTAGGCAGGTGCTTGGCATGAATGAGAAGTGACTTTCCTGGAG 3201 TCCCTCAGTAGAGGATGAGATAGCAGGGATTAGGCCACAGTCTCAGATCCTGATCTTTTTTCTTCCTAGGAAAGCATACA 3281 TAACTTGTGTCTGCAGAATCAGTGTGGGATGATTTTGCTGGCCCAAGGCTTCAGCGAGAGGGAGAAGAGAGGTCACTACA 3361 GCCCTCCTGTGGGTAAAAGCAGCTCTCTTATAAACCTGCCTCCATGCAGTGGGGTGGGGGTAAGGGTGGGTGACAGCAAA 3441 GAGGTTGAGGAACCTCCCTGGGTTTGGGGAGTGAGAGCTTCCATGTTCCCTTAATGTCCTAGGTTAATTCATAAGGCATC 3521 TGAGTCCTGGGTCTCACCCAGCCTCACAGAGAGAAAAACTGTCCCTGAGGGTGTCCCCTCCCACTCAAAGGTAGAAAGAG 3601 ATTGAGCCAGGAACTGCCCTCATATCCTCTGCTCTGCCCCTTCCCTTCCCTTTCCTCTGCCCCTCCCACCTAAAGCTGTT 3681 TGGGGCCCTTTCTCAGAGCCCTGGGTGGTGGCAGGCAGGGAGGAGTCCCAAGATCCTGGTGGCCCTGAGCCCCATGCTAT 3761 GGTTGCCAGATTTGGCAAATAAAAATACAGGATGTCCAGTTACATTTGAATTTCAGTTCAACAACAAACAATTATTAAGT 3841 GTAAATATGTCCTAGGCAAATAGTTGGGACATATACTAAAAAATAATTTGTTGTTTATCTGAAATTCAAATGTAACTGGT 3921 CATCCTGCATTGTGTCTGGGAACCCTACCCTATGACTTTTCCCCCTCTCCCTTTGGTCCCAAGGGGCCAGGAACCCCAAG 4001 GATTTGACTTAACCAGTTTTTTGAACTGCAATATTGAGAAGGGGACACTGTGACTTGAAGACACATGAATTACTTTATTT 4081 TTTAAGCAACAACAAAATAAGAACCTTCTGAAGCCATTTGAGCCTCATCTGCCCCCATCCGTGTATATTTAATTATATAT 4161 AAAAGAAGATAATTACCTAGAAACATATGAACAGAATCTTGTTTAATCAAGATGCATGTCTATAACTTTCTGTAAATAGC 4241 CGCATGGCAATGCTGAGAGTCCCCTTGATCCCCAACCTCAAACCCATTTTACAGAACTGGTTGAGGCTGCTCCTTTGATT 4321 TTATGTCGTGTAAAGTCTTTGTTCCCCAGCCCCACCCCTGCCTCCTCCCATCGGGAAACCCCCCATGGGAGTCATCAGTG 4401 GGCGGGAGTCGGTGCCTGCTCCAGTCCAGCCCTGCCTTGGGAGATGCTGGAGGACCCTGTCGCCCTGAAGGCCTGTTTGC 4481 TGCACATCTGCCTGCAGAGCCAAACCTCAGGGCCCGGTGCAGTGTCCAGCCTGGTATCTGGCATCCCAGTAGCTTCCATG 4561 TTCTGTGTATGTGTGTGGTGTGCCCCTTCCTCCCACTGTTTGAATTCACTGAAAAGCCATAAAGGGGGCCTCCTGCTGGA 4641 GATTTGGCCTCCCTTGGCTCCTCCCAGGAGCCCCCATGTCTCTCCAACTGGCTCCCCACAGACCACTTCTGAAGGGCTCA 4721 CCTGTTGTCACTCCCTCCTGCTCCCTCAGTCCCGTGTCATGAGAATGGACGGTGTCCAGGGCTTCCGGTGGGGTCTCAGG 4801 AGATGCCCATGCTGGCCCTGCCCGAGCTGGCTTTCTCGGCCTGGGTTCACAGTTCAGCTCCATCTCTACGCTGGGCGAGG 4881 AGCAGACAGCAGTGGGACTCCATGGTTCTGGATACCTTTCCTGGGGTCCCTGTGGAGGCAACCAGGATTTTCAGGAGCAG 4961 CCAGTCAGCAGCTCAGCCAGGGATGACAGAACCATCCCTGCTTACTCACCTCTGTAGTGTGAGGGTCTGTGGGTGGTGAT 5041 GGAGGAGGGACTCAGGGAGAGGCCGGTGAATACAGGGGCTGACGCTCTTCCCTCGTGCATCCTCCTGCAGTCTGACAGAA 5121 AGCAGCCCAATAGCGGGGCAACCTCAGGGCTACCAGCGATCCCCTGAGAGTGGGGTGGGCAGGTTCAGCTGTGAGAGAGG 5201 CTCAGGCAGAGCAGGTGTGGACTAAGTCCCCTGACCTTCACACCTGCTCCCCAGAGAAGCCCCAGCCAGTTGCACCAAGT 5281 AGCAGAGGTGAGTAGAGGGGCCTGGGGGCTTCCAAGGCCCCAGGTCATCCTGTTGAACTGAGAGGGACAGGTAGCCCCCC 5361 TGCCTGCGGCCCCTGGCCCCATGGGCACCTGAGGGCAGTACTGCATGGGAAGAGCCCAGGATGCCTCAGGCCTGGCAACT 5441 GTGACAAGTATGAGGAAGGAGAGAGAACGGGAAGGGAATCAGGCAGGGCGCATTCGAGGAGGCCAGAGGTGGCGAGGCAG 5521 GCTTGCCCTGCACAAACCACAACAGAAGTTGCACACAGAAGTCCCAGGGACCTTTGTGCTGGGAACTGAAAGAGTGGGGA 5601 AGGTGGAGGGGACCATTTCAGAGCAGGCTGGAATCAGGTGCTTGGACCAGTGAAGACATGTCTTGCTTCCTCCAGCTCTC 5681 TCTGGGGCCCTCCCACTCTCCACACCCACAGCAGAGACAAATTGAGGCAAGAGTTGAGAGAGCATCTGTCTGGTGAGGTG 5761 ATGGGAGCAGTGTGCATGGGGCACCAGGAGTTCCTCCATCCCACCTGCCTTAGCGATCAGGACTTTAGGGGGGCCTCTTC 5841 AAAGATAGTGACCCTTCTGCCCTGACTCCTGCCCATCTAAGGACTTGATTTGCTGCTTTCTGAAAACCCTGGGGCTGAAA 5921 ACTTCAAAATCAGGGCCTGGCAGAGCCTAGCTTCGCCAAGGTCAGCCCACCAGGAGCCCTGCCTTCGTCTCCATAGGAAG 6001 GACACATGTACAGCCCTTGCCCCCGGCCCTCTCATTCCCACTTCTGCTTGGCAATGCTCTCCATCTCCCTTATGTGGACT 6081 CTTGTTCTTGTCTGATCTCTTGTCAAATTGTTATTTTGTAATGAACTGCGTCTCCTTATTAAAGAAATGAGCTGAAAGAA 6161 A Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
miRNA:Target | ---- | |||||||||
Validation Method |
|
|||||||||
Conditions | Flp-In T-REx 293-hAGO1 cells | |||||||||
Location of target site | 3'UTR | |||||||||
Original Description (Extracted from the article) |
...
Validation of interactions identified by CLASH suppports their reliability.
... - Helwak A; Kudla G; Dudnakova T; Tollervey D, 2013, Cell. |
|||||||||
miRNA-target interactions (Provided by authors) |
|
|||||||||
Article |
- Helwak A; Kudla G; Dudnakova T; Tollervey D - Cell, 2013
MicroRNAs (miRNAs) play key roles in gene regulation, but reliable bioinformatic or experimental identification of their targets remains difficult. To provide an unbiased view of human miRNA targets, we developed a technique for ligation and sequencing of miRNA-target RNA duplexes associated with human AGO1. Here, we report data sets of more than 18,000 high-confidence miRNA-mRNA interactions. The binding of most miRNAs includes the 5' seed region, but around 60% of seed interactions are noncanonical, containing bulged or mismatched nucleotides. Moreover, seed interactions are generally accompanied by specific, nonseed base pairing. 18% of miRNA-mRNA interactions involve the miRNA 3' end, with little evidence for 5' contacts, and some of these were functionally validated. Analyses of miRNA:mRNA base pairing showed that miRNA species systematically differ in their target RNA interactions, and strongly overrepresented motifs were found in the interaction sites of several miRNAs. We speculate that these affect the response of RISC to miRNA-target binding.
LinkOut: [PMID: 23622248]
|
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
91 hsa-miR-125b-2-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT038624 | HN1L | Jupiter microtubule associated homolog 2 | 1 | 1 | ||||||||
MIRT038625 | KDELC2 | KDEL motif containing 2 | 1 | 1 | ||||||||
MIRT038626 | ABHD15 | abhydrolase domain containing 15 | 1 | 1 | ||||||||
MIRT038627 | PPP1R12C | protein phosphatase 1 regulatory subunit 12C | 1 | 1 | ||||||||
MIRT038628 | MSANTD4 | Myb/SANT DNA binding domain containing 4 with coiled-coils | 1 | 1 | ||||||||
MIRT038629 | ASH2L | ASH2 like histone lysine methyltransferase complex subunit | 1 | 1 | ||||||||
MIRT038630 | USP22 | ubiquitin specific peptidase 22 | 1 | 1 | ||||||||
MIRT038631 | CSTB | cystatin B | 1 | 1 | ||||||||
MIRT038632 | SYT2 | synaptotagmin 2 | 1 | 1 | ||||||||
MIRT038633 | NDUFS7 | NADH:ubiquinone oxidoreductase core subunit S7 | 1 | 1 | ||||||||
MIRT038634 | MTA2 | metastasis associated 1 family member 2 | 1 | 1 | ||||||||
MIRT053086 | IGF1R | insulin like growth factor 1 receptor | 3 | 1 | ||||||||
MIRT055788 | PLEKHA1 | pleckstrin homology domain containing A1 | 2 | 12 | ||||||||
MIRT061248 | AMOTL1 | angiomotin like 1 | 2 | 10 | ||||||||
MIRT061649 | BTG2 | BTG anti-proliferation factor 2 | 2 | 6 | ||||||||
MIRT079046 | TNRC6C | trinucleotide repeat containing 6C | 2 | 4 | ||||||||
MIRT084583 | BCL2L11 | BCL2 like 11 | 2 | 8 | ||||||||
MIRT093523 | GALNT7 | polypeptide N-acetylgalactosaminyltransferase 7 | 2 | 2 | ||||||||
MIRT097383 | LHFPL2 | LHFPL tetraspan subfamily member 2 | 2 | 4 | ||||||||
MIRT098030 | SOBP | sine oculis binding protein homolog | 2 | 2 | ||||||||
MIRT186262 | TCEB3 | elongin A | 2 | 2 | ||||||||
MIRT187284 | DAZAP2 | DAZ associated protein 2 | 2 | 10 | ||||||||
MIRT361113 | LRRC1 | leucine rich repeat containing 1 | 2 | 2 | ||||||||
MIRT443585 | FAM84B | family with sequence similarity 84 member B | 2 | 2 | ||||||||
MIRT452249 | TRAM1 | translocation associated membrane protein 1 | 2 | 2 | ||||||||
MIRT476289 | GMFB | glia maturation factor beta | 2 | 8 | ||||||||
MIRT483871 | MRPL12 | mitochondrial ribosomal protein L12 | 2 | 2 | ||||||||
MIRT484250 | ANK1 | ankyrin 1 | 2 | 2 | ||||||||
MIRT499251 | VAV3 | vav guanine nucleotide exchange factor 3 | 2 | 4 | ||||||||
MIRT502270 | HNRNPA1 | heterogeneous nuclear ribonucleoprotein A1 | 2 | 4 | ||||||||
MIRT504652 | RPL9 | ribosomal protein L9 | 2 | 6 | ||||||||
MIRT505210 | UBN2 | ubinuclein 2 | 2 | 6 | ||||||||
MIRT512690 | POP1 | POP1 homolog, ribonuclease P/MRP subunit | 2 | 2 | ||||||||
MIRT517341 | ZNF529 | zinc finger protein 529 | 2 | 4 | ||||||||
MIRT518946 | LSG1 | large 60S subunit nuclear export GTPase 1 | 2 | 2 | ||||||||
MIRT520866 | SUGT1 | SGT1 homolog, MIS12 kinetochore complex assembly cochaperone | 2 | 2 | ||||||||
MIRT521236 | SAR1A | secretion associated Ras related GTPase 1A | 2 | 2 | ||||||||
MIRT528324 | GIGYF2 | GRB10 interacting GYF protein 2 | 2 | 2 | ||||||||
MIRT533297 | USP46 | ubiquitin specific peptidase 46 | 2 | 2 | ||||||||
MIRT541024 | WEE1 | WEE1 G2 checkpoint kinase | 2 | 4 | ||||||||
MIRT544034 | ERRFI1 | ERBB receptor feedback inhibitor 1 | 2 | 2 | ||||||||
MIRT547037 | POGZ | pogo transposable element derived with ZNF domain | 2 | 2 | ||||||||
MIRT556102 | MOAP1 | modulator of apoptosis 1 | 2 | 2 | ||||||||
MIRT558320 | DR1 | down-regulator of transcription 1 | 2 | 2 | ||||||||
MIRT558520 | CSRNP3 | cysteine and serine rich nuclear protein 3 | 2 | 2 | ||||||||
MIRT566230 | PTMA | prothymosin, alpha | 2 | 4 | ||||||||
MIRT568437 | ARPP19 | cAMP regulated phosphoprotein 19 | 2 | 2 | ||||||||
MIRT570584 | OTUD7B | OTU deubiquitinase 7B | 2 | 2 | ||||||||
MIRT571384 | JKAMP | JNK1/MAPK8-associated membrane protein | 2 | 2 | ||||||||
MIRT572798 | SIGLEC14 | sialic acid binding Ig like lectin 14 | 2 | 2 | ||||||||
MIRT573864 | C9orf78 | chromosome 9 open reading frame 78 | 2 | 2 | ||||||||
MIRT609930 | SLC38A1 | solute carrier family 38 member 1 | 2 | 4 | ||||||||
MIRT610437 | CSMD2 | CUB and Sushi multiple domains 2 | 2 | 2 | ||||||||
MIRT614407 | MURC | caveolae associated protein 4 | 2 | 2 | ||||||||
MIRT618625 | GREB1 | growth regulation by estrogen in breast cancer 1 | 2 | 2 | ||||||||
MIRT620605 | SAP30 | Sin3A associated protein 30 | 2 | 2 | ||||||||
MIRT635313 | FAM179A | TOG array regulator of axonemal microtubules 2 | 2 | 2 | ||||||||
MIRT635918 | GLTSCR2 | NOP53 ribosome biogenesis factor | 2 | 2 | ||||||||
MIRT638507 | MAP3K9 | mitogen-activated protein kinase kinase kinase 9 | 2 | 2 | ||||||||
MIRT640597 | TM9SF4 | transmembrane 9 superfamily member 4 | 2 | 2 | ||||||||
MIRT644066 | IQCE | IQ motif containing E | 2 | 2 | ||||||||
MIRT648287 | TRAPPC2L | trafficking protein particle complex 2 like | 2 | 2 | ||||||||
MIRT653089 | SSR3 | signal sequence receptor subunit 3 | 2 | 2 | ||||||||
MIRT654651 | PTAFR | platelet activating factor receptor | 2 | 2 | ||||||||
MIRT658084 | FOXR2 | forkhead box R2 | 2 | 2 | ||||||||
MIRT665306 | ZBTB37 | zinc finger and BTB domain containing 37 | 2 | 2 | ||||||||
MIRT665974 | SYTL4 | synaptotagmin like 4 | 2 | 2 | ||||||||
MIRT674905 | RASSF9 | Ras association domain family member 9 | 2 | 2 | ||||||||
MIRT680085 | THAP1 | THAP domain containing 1 | 2 | 2 | ||||||||
MIRT681487 | DIP2A | disco interacting protein 2 homolog A | 2 | 2 | ||||||||
MIRT691243 | DFNB59 | pejvakin | 2 | 2 | ||||||||
MIRT692361 | AGTRAP | angiotensin II receptor associated protein | 2 | 2 | ||||||||
MIRT693034 | MB21D1 | Mab-21 domain containing 1 | 2 | 2 | ||||||||
MIRT694478 | LRTOMT | leucine rich transmembrane and O-methyltransferase domain containing | 2 | 2 | ||||||||
MIRT696069 | ZNF264 | zinc finger protein 264 | 2 | 2 | ||||||||
MIRT696579 | TTC21B | tetratricopeptide repeat domain 21B | 2 | 2 | ||||||||
MIRT696759 | MTFMT | mitochondrial methionyl-tRNA formyltransferase | 2 | 2 | ||||||||
MIRT697306 | ZNF652 | zinc finger protein 652 | 2 | 2 | ||||||||
MIRT698736 | STX12 | syntaxin 12 | 2 | 2 | ||||||||
MIRT701055 | PARP2 | poly(ADP-ribose) polymerase 2 | 2 | 2 | ||||||||
MIRT701197 | OTUD3 | OTU deubiquitinase 3 | 2 | 2 | ||||||||
MIRT701334 | NSD1 | nuclear receptor binding SET domain protein 1 | 2 | 2 | ||||||||
MIRT703617 | FBXO45 | F-box protein 45 | 2 | 2 | ||||||||
MIRT708893 | ZNF780A | zinc finger protein 780A | 2 | 2 | ||||||||
MIRT711621 | DGKH | diacylglycerol kinase eta | 2 | 2 | ||||||||
MIRT713744 | TMEM81 | transmembrane protein 81 | 2 | 2 | ||||||||
MIRT715060 | TMTC1 | transmembrane and tetratricopeptide repeat containing 1 | 2 | 2 | ||||||||
MIRT719711 | CD101 | CD101 molecule | 2 | 2 | ||||||||
MIRT720293 | DLGAP3 | DLG associated protein 3 | 2 | 2 | ||||||||
MIRT722605 | CCDC152 | coiled-coil domain containing 152 | 2 | 2 | ||||||||
MIRT724565 | ACSBG1 | acyl-CoA synthetase bubblegum family member 1 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|